FLT3 and acute myeloid leukemia: Complementary to studies by these groups [12, 14], our unbiased approach provides genetic validation for targeting these genes, assures that the mechanisms underlying the synergy are sound, and extends preclinical work advancing clinical translatability of this combination—including demonstrating the combination of FDA-approved FLT3 inhibitors with venetoclax in vivo against multiple models of FLT3-ITD-driven AML beyond the previously studied MV4-11 xenograft model.